Amyris Downgraded by Cowen and Company to “Underperform” (AMRS)
Amyris (NASDAQ:AMRS) was downgraded by equities research analysts at Cowen and Company from a “market perform” rating to an “underperform” rating in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports.
Amyris (NASDAQ:AMRS) opened at 5.29 on Thursday. Amyris has a 52 week low of $2.17 and a 52 week high of $6.11. The stock has a 50-day moving average of $3.11 and a 200-day moving average of $2.75. The company’s market cap is $403.5 million.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.32) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.30) by $0.02. The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $13.59 million. During the same quarter last year, the company posted ($0.22) earnings per share. Amyris’s revenue was down 63.4% compared to the same quarter last year.
Amyris, Inc, formerly Amyris Biotechnologies, Inc develops and provides renewable compounds for a variety of markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.